Priapism

Priapism is a prolonged penile erection lasting >4 hours, unrelated to sexual stimulation, and is classified as ischemic (low-flow, 95% of cases), non-ischemic (high-flow), or stuttering (recurrent ischemic). Ischemic priapism is a true urological emergency — a compartment syndrome of the penis — requiring time-sensitive intervention to prevent irreversible erectile dysfunction. [1-3]

The following algorithm outlines the stepwise management approach:

• Duration of erection — the single most critical factor; >4 hours defines priapism, >24 hours associated with 30–70% ED rates, >36–48 hours often requires surgical intervention [5-6]
• Presence/absence of pain (ischemic = painful and rigid; non-ischemic = typically painless and partially tumescent) [1][7]
• Sexual stimulation or arousal preceding onset
• Prior episodes of priapism or stuttering episodes (<3 hours, self-resolving) — a risk factor for major ischemic events [8]
• Medication history: intracavernosal injections (alprostadil, papaverine), antipsychotics, recreational drugs (cocaine, marijuana)
• History of sickle cell disease or other hemoglobinopathy
• Recent perineal/penile trauma (suggests non-ischemic) [7][9]
• Timing: stuttering priapism often occurs during early morning hours or sleep [10]

• Erection lasting >4 hours — irreversible tissue damage begins [2][10]
• Fully rigid corpora with painful erection and soft glans (classic ischemic priapism) [11]
• Duration >24 hours: widespread smooth muscle necrosis, nerve attrition, and trabecular fibrosis become progressive [2]
• Duration >36–48 hours: high likelihood of permanent ED; surgical intervention (shunt or prosthesis) should be strongly considered [1][6]
• Dark, deoxygenated blood on aspiration (pO₂ <30 mmHg, pH <7.25) confirms ischemia [11]
• Signs of systemic toxicity in SCD patients (acute chest syndrome, sepsis)

Causative medications

• Antipsychotics (especially those with high α₁-adrenergic affinity): risperidone, chlorpromazine, olanzapine, quetiapine [1][12]
• Intracavernosal vasoactive agents: alprostadil, papaverine, phentolamine [7]
• Trazodone, SSRIs, anticoagulants (heparin, warfarin)
• Recreational drugs: cocaine, marijuana, alcohol [12]
• PDE5 inhibitors (rare, but reported)
• Testosterone replacement therapy

Treatment medications

• Intracavernosal phenylephrine (first-line): 100–500 mcg every 3–5 minutes (dilute 1 mg in 19 mL NS = 500 mcg/mL); 74–94% success rate [2][13-14]
• Oral terbutaline (0.25–0.5 mg SQ or 5 mg PO) — modest efficacy (~25%), may be tried while preparing for aspiration [13]
• Oral pseudoephedrine (60 mg) and midodrine (15–30 mg) — limited evidence, inconsistent results [7]

Prophylaxis for stuttering priapism: PDE5 inhibitors (sildenafil/tadalafil), ketoconazole + prednisone, baclofen, dutasteride, hydroxyurea (SCD), self-injection phenylephrine at home [7]

Contraindicated: RBC transfusion is not indicated as primary treatment for acute priapism in SCD [8]

• Hydration is critical, especially in SCD patients — oral and IV fluids are part of initial supportive management [8][11]
• Avoid alcohol and recreational drug use (cocaine, marijuana) as triggers [12]
• No specific dietary triggers for idiopathic priapism, but dehydration and cold exposure may precipitate SCD-related episodes

• Hematologic: fatigue, jaundice, bone pain (SCD crisis), easy bruising
• Genitourinary: prior erectile dysfunction, urinary symptoms, hematuria
• Neurologic: spinal cord symptoms, perineal numbness (cauda equina can cause priapism)
• Psychiatric: medication changes (antipsychotics, antidepressants)
• Oncologic: weight loss, lymphadenopathy, abdominal fullness (leukemia, pelvic malignancy)
• Trauma: recent perineal/penile injury, straddle injury, cycling

• Sickle cell disease or sickle cell trait — priapism affects ~35–40% of males with SCD [8][11]
• Family history of hemoglobinopathies (HbSS, HbSC, HbS-β thalassemia)
• G6PD deficiency [12]
• History of prior priapism episodes and how they resolved
• Psychiatric history and current psychotropic medications
• Substance use history (cocaine, marijuana, alcohol)

• Sickle cell disease — most common cause in children and a leading cause in adults [9][15]
• Antipsychotic medications — especially risperidone, chlorpromazine [12]
• Intracavernosal injection therapy for ED [7]
• Hematologic malignancies (leukemia, multiple myeloma)
• G6PD deficiency [12]
• Cocaine and recreational drug use
• Spinal cord injury or neurologic disease
• Perineal/penile trauma (non-ischemic type) [7]
• Age: bimodal peak — 5–10 years and 20–50 years [9]

• Ischemic (low-flow) priapism — 95% of cases; painful, rigid corpora, soft glans; urologic emergency [16]
• Non-ischemic (high-flow) priapism — post-traumatic arterio-cavernosal fistula; painless, partially tumescent; NOT an emergency [7]
• Stuttering priapism — recurrent self-limited ischemic episodes (<3–4 hours) [7]
• Prolonged iatrogenic erection — following intracavernosal injection; distinct pathology from true priapism [7]
• Sleep-related painful erections — distinct from ischemic priapism, no underlying ischemia [7]
• Penile fracture — acute pain with detumescence, not erection
• Peyronie's disease — curvature without prolonged erection
• Malignant priapism — metastatic infiltration of corpora (bladder, prostate, rectal cancer)
• Cauda equina syndrome — may present with priapism plus neurologic deficits

• Sickle cell disease or other hemoglobinopathy
• Prior priapism episodes — number, duration, treatment, and outcome
• Erectile dysfunction (pre-existing vs. post-priapism)
• Hematologic malignancy
• Spinal cord injury or neurologic disease
• Psychiatric illness requiring antipsychotics
• Use of intracavernosal injection therapy
• Prior penile surgery or shunt procedures

• Penile exam: fully rigid corpora cavernosa with a soft glans is pathognomonic for ischemic priapism [11]
• Non-ischemic: partially tumescent, non-tender penis
• Assess for perineal ecchymosis or trauma (suggests non-ischemic etiology)
• Vital signs: monitor BP and HR closely during phenylephrine administration; hypertension, bradycardia, and arrhythmia are potential complications [2]
• Abdominal exam: hepatosplenomegaly (SCD, leukemia)
• Neurologic exam: lower extremity strength, sensation, rectal tone (rule out cauda equina)
• Lymph node exam: inguinal lymphadenopathy (malignancy)

• Corporal blood gas analysis (diagnostic gold standard for subtyping): [1][16]
  • Ischemic: pO₂ <30 mmHg, pCO₂ >60 mmHg, pH <7.25 (dark blood)
  • Non-ischemic: pO₂ >90 mmHg, pCO₂ <40 mmHg, pH 7.35–7.45 (bright red blood)
• CBC with differential — evaluate for leukemia, sickle cell anemia, polycythemia
• Hemoglobin electrophoresis — if SCD not previously diagnosed
• Reticulocyte count — hemolysis assessment in SCD
• Coagulation studies (PT/INR, PTT) — if coagulopathy suspected
• Urine toxicology screen — cocaine and other substances
• Metabolic panel — baseline renal/hepatic function
• LDH, haptoglobin, bilirubin — hemolysis markers in SCD

• Color Doppler ultrasound (CDUS) — first-line imaging; differentiates ischemic (absent/minimal cavernosal arterial flow) from non-ischemic (high-velocity turbulent flow at fistula site) [17-18]
• Point-of-care ultrasound (POCUS) — rapid bedside assessment of cavernosal arterial flow in the ED; can confirm high-flow priapism noninvasively [18-19]
• Penile MRI — useful in delayed presentations to assess extent of corporal necrosis and guide decision-making regarding prosthesis vs. shunt [17]
• CT/MRI — indicated when malignant priapism is suspected (pelvic mass, metastatic disease) [17]
• Catheter angiography — reserved for non-ischemic priapism when embolization is planned [17]
• Imaging is often unnecessary in straightforward acute ischemic priapism where history and corporal blood gas are diagnostic [16]

• Corporal blood gas analysis — both diagnostic and therapeutic (aspiration is part of treatment) [1][16]
• Penile duplex Doppler ultrasound — for equivocal cases, non-ischemic priapism evaluation, and post-treatment follow-up [7][17]
• STIFF protocol (Sonography to Identify Forward Flow) — novel dynamic POCUS technique applying controlled glans pressure while monitoring cavernosal flow [19]
• Selective pudendal arteriography — for non-ischemic priapism prior to embolization [20]
• No validated clinical scoring systems exist specifically for priapism severity, though duration >36 hours and non-SCD etiology predict need for shunting [21]

• ECG monitoring is recommended during intracavernosal phenylephrine administration, particularly in patients with cardiovascular disease [2]
• Watch for reflex bradycardia, hypertension, and arrhythmias secondary to phenylephrine
• Baseline ECG if the patient has known cardiac disease or is on QT-prolonging medications (many antipsychotics that cause priapism also prolong QT)

Priapism is classified into three subtypes with distinct urgency levels:

Complications: Permanent erectile dysfunction (most feared), penile fibrosis, penile shortening/deformity, corporeal necrosis, and penile gangrene in extreme cases. [2][23]

Ischemic priapism — stepwise approach: [1-2][24]

• Supportive care: IV fluids, analgesia (opioids as needed), anxiolysis
• Corporal aspiration ± irrigation with normal saline — use a 16–18G needle inserted into the lateral corpus cavernosum at 2 or 10 o'clock position; aspirate until bright red blood returns
• Intracavernosal phenylephrine (first-line sympathomimetic):
  • Dilute: 1 mg phenylephrine in 19 mL NS (= 50 mcg/mL) or use higher concentrations per institutional protocol
  • Inject 100–500 mcg every 3–5 minutes; max ~1000 mcg in 1 hour
  • Monitor BP and HR continuously
  • Success rate: 74–94% [13-14]
• Surgical shunt (if aspiration + phenylephrine fails within first 24–48 hours):
  • Distal shunts first (Winter percutaneous, Al-Ghorab open) [23][25]
  • Proximal shunts (Quackels, Grayhack) — higher morbidity, generally avoided [25]
• Penile prosthesis — indicated for refractory priapism >36–48 hours or failed shunting; early implantation preferred over delayed [1][6][26]

Non-ischemic priapism: [7]

• Observation for 4 weeks initially (not an emergency)
• Selective arterial embolization if persistent and bothersome (success 85.7–100%) [25]

SCD-specific considerations: [7-8]

• Do NOT delay urologic intervention for exchange transfusion
• IV hydration, oxygen, analgesia concurrent with urologic management
• Simple transfusion to Hgb 9–10 g/dL if general anesthesia required for shunting
• Hydroxyurea or chronic transfusion program for recurrence prevention

• Admission criteria: priapism >4–6 hours requiring aspiration/phenylephrine, failed initial treatment, need for surgical intervention, SCD patients requiring monitoring, hemodynamic instability during treatment [7]
• Observation: partial detumescence after treatment — serial exams, interval assessment of corporal blood flow [4]
• Discharge criteria: complete detumescence achieved, stable vitals, pain controlled, underlying etiology addressed or follow-up arranged
• Urology consultation: all cases of ischemic priapism >4 hours; emergent for failed aspiration/phenylephrine [7][10]
• Hematology consultation: SCD patients, suspected hematologic malignancy [7]

• Follow-up with urology within 1–2 weeks for erectile function assessment and counseling [4]
• Return immediately if erection recurs and lasts >2–4 hours (especially in stuttering priapism patients) [7]
• Counsel on home self-injection of phenylephrine for patients with recurrent ischemic priapism, per urologist guidance [7]
• Discuss medication changes with prescribing psychiatrist if antipsychotic-induced (switch to agents with lower α₁ affinity, e.g., amisulpride) [12]
• Counsel that erectile dysfunction is a common sequela, especially with prolonged episodes; early follow-up for assessment and potential prosthesis discussion [5][26]
• SCD patients: reinforce hydration, avoidance of triggers (cold, dehydration, stress), and adherence to hydroxyurea or transfusion program [8][11]
• Expected recovery: if treated within 12–24 hours, erectile function preservation is more likely; beyond 24–48 hours, ED rates rise significantly (30–70%) [5]

1. An Update on Mechanisms and Treatment Options for Priapism. — Pang KH, Alnajjar HM, Lal A, Muneer A. Nature Reviews. Urology. 2025.

2. An Overview of Emergency Pharmacotherapy for Priapism. — Graham BA, Wael A, Jack C, Rohan MA, Wayne HJG. Expert Opinion on Pharmacotherapy. 2022.

3. Management of Priapism: 2021 Update. — Ericson C, Baird B, Broderick GA. The Urologic Clinics of North America. 2021.

4. Priapism. — Akash A. Kapadia, Kevin Ostrowski, Thomas J. Walsh A Clinical Guide to Urologic Emergencies. 2021.

5. Conservative and Medical Treatments of Non-Sickle Cell Disease-Related Ischemic Priapism: A systematic Review by the EAU Sexual and Reproductive Health Panel. — Capogrosso P, Dimitropolous K, Russo GI, et al. International Journal of Impotence Research. 2024.

6. Non-Surgical vs Surgical Management for Major Ischemic Priapism of 36 hours Duration. — El-Achkar A, Arbuiso A, Filho NM, et al. The Journal of Sexual Medicine. 2025.

7. The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/­SMSNA Guideline. — Bivalacqua TJ, Allen BK, Brock GB, et al. The Journal of Urology. 2022.

8. Sickle Cell Disease: A Review. — Kavanagh PL, Fasipe TA, Wun T. The Journal of the American Medical Association. 2022.

9. Treatments for Priapism in Boys and Men With Sickle Cell Disease. — Chinegwundoh FI, Smith S, Anie KA. The Cochrane Database of Systematic Reviews. 2020.

10. Health Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report. — Yates AM, Aygun B, Nuss R, Rogers ZR. Pediatrics. 2024.

11. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. — National Heart, Lung, and Blood Institute. 2014.

12. Risperidone-Induced Priapism: A Systematic Review of Risk Factors, Comprehensive Assessment, and Management Recommendations. — Owusu-Antwi P, Muhialdain M, Atodaria P, et al. Journal of Clinical Psychopharmacology. 2026.

13. Effect of Phenylephrine and Terbutaline on Ischemic Priapism: A Retrospective Review. — Martin C, Cocchio C. The American Journal of Emergency Medicine. 2016.

14. Use of High-Dose Phenylephrine in the Treatment of Ischemic Priapism: Five-Year Experience at a Single Institution. — Ridyard DG, Phillips EA, Vincent W, Munarriz R. The Journal of Sexual Medicine. 2016.

15. Priapism in the Paediatric and Adolescent Population. — Mushtaq A, Jayasimha S, To WKL, Mushtaq I. International Journal of Impotence Research. 2024.

16. Standard Operating Procedures for Priapism. — Burnett AL, Sharlip ID. The Journal of Sexual Medicine. 2013.

17. Review of the Role of Imaging in the Diagnosis of Priapism. — von Stempel C, Walkden M, Kirkham A. International Journal of Impotence Research. 2024.

18. Point-of-Care Ultrasound Diagnosis of High Flow Priapism. — McHugh K, Gibbons RC. The Journal of Emergency Medicine. 2022.

19. A Novel Approach to Priapism Doppler Assessment: Sonography to Identify Forward Flow (STIFF Protocol). — Leamon A, Montoya K, Shokoohi H. The Journal of Emergency Medicine. 2025.

20. Diagnosis and Treatment of Priapism: Experience With 5 Cases. — Goto T, Yagi S, Matsushita S, et al. Urology. 1999.

21. Using Artificial Intelligence to Predict Surgical Shunts in Men With Ischemic Priapism. — Masterson TA, Parmar M, Tradewell MB, et al. The Journal of Urology. 2020.

22. Evaluation and Management of Priapism: 2009 Update. — Huang YC, Harraz AM, Shindel AW, Lue TF. Nature Reviews. Urology. 2009.

23. The Surgical Management of Ischaemic Priapism. — Johnson MJ, Kristinsson S, Ralph O, Chiriaco G, Ralph D. International Journal of Impotence Research. 2020.

24. A Narrative Review of Initial Treatment for Ischemic Priapism. — Lumbiganon S, Moukhtar Hammad MA, Azad B, Yafi FA. International Journal of Impotence Research. 2024.

25. Surgical and Minimally Invasive Treatment of Ischaemic and Non-Ischaemic Priapism: A Systematic Review by the EAU Sexual and Reproductive Health Guidelines Panel. — Milenkovic U, Cocci A, Veeratterapillay R, et al. International Journal of Impotence Research. 2024.

26. Early Penile Prosthesis Implantation in Refractory Ischaemic Priapism: A Narrative Review. — Calopedos R, Trubbia D, Ralph D, Lee WG. International Journal of Impotence Research. 2025.